A new dawn in cardio and vascular protection v. cardiovascular high-risk patients: treat to protect.
Fujita
Toshiro
T
Department of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan. fujita-dis@h.u-tokyo.ac.jp
Mancia
Giuseppe
G
Jakobsen
Anne
A
Heroys
Jose
J
Ralph
Ann
A
Rees
Tomas
T
Shaw
Michael
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D006801:Humans; D011322:Primary Prevention / Q000639:trends*; D012307:Risk Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents